Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Cited by (1,051)

Items 301–400 of 1,051

1. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
   Kenji Chamoto, Partha Sarathi Chowdhury, Alok Kumar, Kazuhiro Sonomura, Fumihiko Matsuda, Sidonia Fagarasan, Tasuku Honjo · 2017 · Proceedings of the National Academy of Sciences
2. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor
   Ruffo, Elisa, Wu, Richard C., Bruno, Tullia C., Workman, Creg J., Vignali, Dario A.A. · 2019 · Seminars in Immunology
3. PD ‐1 as a potential target in cancer therapy
   David F. McDermott, Michael B. Atkins · 2013 · Cancer Medicine
4. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer
   Wang, Hai, Rong, Xingyu, Zhao, Gan, Zhou, Yifan, Xiao, Yi, Ma, Ding, Jin, Xi, Wu, Yonglin, Yan, Yuchen, Yang, Hao et al. · 2022 · Cell Metabolism
5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
   Guoying Zhou, Dave Sprengers, Patrick P.C. Boor, Michail Doukas, Hannah M. Schutz, Shanta Mancham, Alexander Pedroza‐González, Wojciech Grzegorz Polak, Jeroen de Jonge, Marcia Patricia Gaspersz et al. · 2017 · Gastroenterology
6. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
   Zhao, Yunlong, Lee, Calvin K., Lin, Chia-Hao, Gassen, Rodrigo B., Xu, Xiaozheng, Huang, Zhe, Xiao, Changchun, Bonorino, Cristina, Lu, Li-Fan, Bui, Jack D. et al. · 2019 · Immunity
7. Neutrophils dominate the immune cell composition in non-small cell lung cancer
   Julia Kargl, Stephanie Busch, Grace H. Y. Yang, Kyoung-Hee Kim, Mark L. Hanke, Heather E. Metz, Jesse J. Hubbard, Sylvia M. Lee, David K. Madtes, Martin W. McIntosh et al. · 2017 · Nature Communications
8. Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
   Corsello, Salvatore Maria, Barnabei, Agnese, Marchetti, Paolo, De Vecchis, Liana, Salvatori, Roberto, Torino, Francesco · 2013 · The Journal of Clinical Endocrinology & Metabolism
9. FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
   Rony Dahan, Emanuela I. Sega, John Engelhardt, Mark Selby, Alan J. Korman, Jeffrey V. Ravetch · 2015 · Cancer Cell
10. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
    Ross A. Stewart, Michelle Morrow, Scott A. Hammond, Kathy A. Mulgrew, Danielle Marcus, Edmund Poon, Amanda Watkins, Stefanie Mullins, Matthieu Chodorge, John L. Andrews et al. · 2015 · Cancer Immunology Research
11. Paradigms on Immunotherapy Combinations with Chemotherapy
    Diego Salas‐Benito, José Luis Perez‐Gracia, Mariano Ponz‐Sarvisé, Maria Esperanza Rodriguez-Ruiz, Iván Martínez‐Forero, Eduardo Castañón Álvarez, José María López-Picazo, Miguel F. Sanmamed, Ignacio Melero · 2021 · Cancer Discovery
12. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai et al. · 2016 · Blood
13. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
    Jiabei He, Ying Hu, Mingming Hu, Baolan Li · 2015 · Scientific Reports
14. Adoptive cellular therapy: A race to the finish line
    Carl H. June, Stanley R. Riddell, Ton N. Schumacher · 2015 · Science Translational Medicine
15. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Xiangjiao Meng, Zhaoqin Huang, Feifei Teng, Ligang Xing, Jinming Yu · 2015 · Cancer Treatment Reviews
16. Emerging cytokine networks in colorectal cancer
    Nathaniel R. West, Sarah McCuaig, Fanny Franchini, Fiona M. Powrie · 2015 · Nature reviews. Immunology
17. Blocking of the PD‐1/PD‐L1 Interaction by a D ‐Peptide Antagonist for Cancer Immunotherapy
    Haonan Chang, Bei‐Yuan Liu, Yun‐Kun Qi, Yang Zhou, Yanping Chen, Kai‐Mai Pan, Wenwen Li, Xiuman Zhou, Weiwei Ma, Caiyun Fu et al. · 2015 · Angewandte Chemie International Edition
18. PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials
    Jason Madore, Ricardo E. Vilain, Alexander Maxwell Menzies, Hojabr Kakavand, James S. Wilmott, Jessica Hyman, Jennifer Holmes Yearley, Richard F. Kefford, John F. Thompson, Georgina Venetia Long et al. · 2014 · Pigment Cell & Melanoma Research
19. PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
    Kevin C. Soares, Agnieszka A. Rucki, Annie A. Wu, Kelly L. Olino, Qian Xiao, Yi Chai, Anthony Wamwea, Elaine O. Bigelow, Eric R. Lutz, Linda L. Liu et al. · 2014 · Journal of Immunotherapy
20. Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Theodore Scott Nowicki, Siwen Hu‐Lieskovan, Antoni Ribas · 2018 · The Cancer Journal
21. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
    Wenfeng Fang, Jianwei Zhang, Shaodong Hong, Jianhua Zhan, Nan Chen, Tao Qin, Yanna Tang, Yaxiong Zhang, Shiyang Kang, Ting Zhou et al. · 2014 · Oncotarget
22. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
    Hallie Wimberly, Jason Robert Brown, Kurt Alex Schalper, Herbert Haack, Matthew R. Silver, Christian Nixon, Veerle Bossuyt, Lajos Pusztai, Donald R. Lannin, David L. Rimm · 2014 · Cancer Immunology Research
23. Programmed death ligand 1 signals in cancer cells
    Anand V. R. Kornepati, Ratna K. Vadlamudi, Tyler Jay Curiel · 2022 · Nature reviews. Cancer
24. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
    Steven C. Katz, Rachel A. Burga, Elise M. McCormack, Lijuan Wang, Wesley Mooring, Gary R. Point, Pranay D. Khare, Mitchell Thorn, Qiangzhong Ma, Brian F. Stainken et al. · 2015 · Clinical Cancer Research
25. Single‐cell RNA sequencing in cancer research
    Yijie Zhang, Dan Wang, Peng Miao, Le Min Tang, Jiawei Ouyang, Fang Xiong, Can Jie Guo, Yanyan Tang, Yujuan Zhou, Qianjin Liao et al. · 2021 · Journal of Experimental & Clinical Cancer Research
26. Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis
    Zhang, Yaqing, Lazarus, Jenny, Steele, Nina G., Yan, Wei, Lee, Ho-Joon, Nwosu, Zeribe C., Halbrook, Christopher J., Menjivar, Rosa E., Kemp, Samantha B., Sirihorachai, Veerin R. et al. · 2020 · Cancer Discovery
27. Dose-Response Association of CD8 + Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
    Ellen L. Goode, Matthew Stephen Block, Kimberly R. Kalli, Robert Alan Vierkant, Wenqian Chen, Zachary C. Fogarty, Aleksandra Gentry‐Maharaj, Aleksandra D. Toloczko, Alexander Hein, Aliecia Bouligny et al. · 2017 · JAMA Oncology
28. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
    Daniela S. Thommen, Jens Schreiner, Philipp Müller, Petra Herzig, Andreas Roller, Anton Belousov, Pablo Umaña, Pavel Pisa, Christian Klein, Marina Bacac et al. · 2015 · Cancer Immunology Research
29. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer
    Christopher J. Halbrook, Costas Andreas Lyssiotis · 2017 · Cancer Cell
30. <i>Roseburia intestinalis</i> generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8 ⁺ T cells
    Kang, Xing, Liu, Changan, Ding, Yanqiang, Ni, Yunbi, Ji, Fenfen, Lau, Harry Cheuk Hay, Jiang, Lanping, Sung, Joseph JY, Wong, Sunny H, Yu, Jun · 2023 · Gut
31. Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
    Chunxiao Xu, Christine F. Brainson, Shohei Koyama, Hongbo Wu, Yanqiu Zhao, Zhao Chen, Grit Sophie Herter-Sprie, Esra A. Akbay, Jeremy H. Tchaicha, Abigail B. Altabef et al. · 2014 · Cancer Cell
32. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
    Curtis A. Clark, Harshita B. Gupta, Gangadhara R. Sareddy, Srilakshmi Pandeswara, Shunhua Lao, Bin Yuan, Justin Michael Drerup, Alvaro Souto Padron, Jose Ramon Conejo-Garcia, Kruthi Murthy et al. · 2016 · Cancer Research
33. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
    Liliang Xia, Yuanyong Liu, Ying Wang · 2019 · The Oncologist
34. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
    Chris Nevala-Plagemann, Manuel M. Hidalgo, Ignacio Garrido‐Laguna · 2019 · Nature Reviews Clinical Oncology
35. Restriction of PD-1 function by <i>cis</i> -PD-L1/CD80 interactions is required for optimal T cell responses
    Sugiura, Daisuke, Maruhashi, Takumi, Okazaki, Il-mi, Shimizu, Kenji, Maeda, Takeo K., Takemoto, Tatsuya, Okazaki, Taku · 2019 · Science
36. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis
    Nathan Edward Reticker-Flynn, Weiruo Zhang, Julia A. Belk, Pamela Antonia Basto, Nichole K. Escalante, Genay O.W. Pilarowski, Alborz Bejnood, Maria M. Martins, Justin A. Kenkel, Ian L. Linde et al. · 2022 · Cell
37. Immunotherapy in ovarian cancer
    Kunle O. Odunsi · 2017 · Annals of Oncology
38. Signal pathways of melanoma and targeted therapy
    Weinan Guo, Huina Wang, Chunying Li · 2021 · Signal Transduction and Targeted Therapy
39. PD-1 Restrains Radiotherapy-Induced Abscopal Effect
    Sean S. Park, Haidong Dong, Xin Liu, Susan M. Harrington, Christopher J. Krco, Michael P. Grams, Aaron Scott Mansfield, Keith M. Furutani, Kenneth R. Olivier, Eugene D. Kwon · 2015 · Cancer Immunology Research
40. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
    Ruea‐Yea Huang, Ariel Francois, AJ Robert McGray, Anthony J. Miliotto, Kunle O. Odunsi · 2016 · OncoImmunology
41. Oncotarget
    Ross-Adams, H, Ball, S, Kate Lawrenson, Halim, S, Russell, R, Clive A Wells, Strand, SH, Orntoft, TF, Larson, M, Armasu, S et al. · 2016 · Oncotarget
42. Alterations of immune response of non-small cell lung cancer with Azacytidine
    John M. Wrangle, Wei Wang, Alexander Koch, Hariharan Easwaran, Helai P. Mohammad, Xiaoyu Pan, Frank P. Vendetti, Wim Van Criekinge, Timothy DeMeyer, Zhengzong Du et al. · 2013 · Oncotarget
43. CIS is a potent checkpoint in NK cell–mediated tumor immunity
    Rebecca B. Delconte, Tatiana B. Kolesnik, Laura F. Dagley, Jai Rautela, Wei Shi, Eva Maria Putz, Kimberley A. Stannard, Jian‐Guo Zhang, Charis E. Teh, Matt Firth et al. · 2016 · Nature Immunology
44. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
    Padrón, Lacey J., Maurer, Deena M., O’Hara, Mark H., O’Reilly, Eileen M., Wolff, Robert A., Wainberg, Zev A., Ko, Andrew H., Fisher, George, Rahma, Osama, Lyman, Jaclyn P. et al. · 2022 · Nature Medicine
45. Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
    Patrizio Caturegli, Giulia Di Dalmazi, Martina Lombardi, Federica Grosso, H. Benjamin Larman, Tatianna Larman, Giacomo Giovanni Taverna, Mirco Cosottini, Isabella Lupi · 2016 · American Journal Of Pathology
46. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer
    Kemp, Samantha B., Cheng, Noah, Markosyan, Nune, Sor, Rina, Kim, Il-Kyu, Hallin, Jill, Shoush, Jason, Quinones, Liz, Brown, Natalie V., Bassett, Jared B. et al. · 2023 · Cancer Discovery
47. CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
    Hye‐Jung Kim, Harvey Cantor · 2014 · Cancer Immunology Research
48. Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression
    Jingjing Cong, Xianwei Wang, Xiaohu Zheng, Dong Wang, Binqing Fu, Rui Sun, Zhigang Tian, Haiming Wei · 2018 · Cell Metabolism
49. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
    Karthik S. Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye Karen Danoff · 2018 · CHEST Journal
50. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
    Gary Middleton, Paul Silcocks, Trevor F. Cox, Juan W. Valle, Jonathan Wadsley, DAVID J. PROPPER, Fareeda Y. Coxon, Paul J. Ross, Srinivasan Madhusudan, Tom W. Roques et al. · 2014 · The Lancet Oncology
51. Combination immunotherapy: a road map
    Patrick Alexander Ott, Frank Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton, Jedd D. Wolchok · 2017 · Journal for ImmunoTherapy of Cancer
52. Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
    Pia Kvistborg, Daisy Philips, Sander Kelderman, Lois Hageman, Christian H. H. Ottensmeier, Débora Joseph‐Pietras, Marij J.P. Welters, Sjoerd van der Burg, Ellen Kapiteijn, Olivier Alain Michielin et al. · 2014 · Science Translational Medicine
53. Targeting PD-1/PD-L1 interactions for cancer immunotherapy
    Laurence Zitvogel, Guido Kroemer · 2012 · OncoImmunology
54. PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
    Evan J. Lipson, Jeremy G. Vincent, Myriam Loyo, Luciane Tsukamoto Kagohara, Brandon S. Luber, Hao Wang, Haiying Xu, Suresh K. Nayar, Timothy S. Wang, David Sidransky et al. · 2013 · Cancer Immunology Research
55. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
    Jake S. O’Donnell, Daniela Massi, Michele W.L. Teng, Mario Mandalà · 2017 · Seminars in Cancer Biology
56. Immunologic tumor microenvironment modulators for turning cold tumors hot
    Gholamreza Reza Khosravi, Samaneh Mostafavi, Sanaz Bastan, Narges Ebrahimi, Roya Safari Gharibvand, Nahid Eskandari · 2024 · 癌症：英文版
57. LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
    Feng Xu, Jing Liu, Di Liu, Biao Liu, Min Wang, Zhiyuan Hu, Xuemei Du, Tang Li, Fuchu He · 2014 · Cancer Research
58. Frequent expression of PD‐L1 on circulating breast cancer cells
    Martine Mazel, William Jacot, Klaus Pantel, Kai Bartkowiak, Delphine Topart, Laure Cayrefourcq, Delphine Rossille, Thierry Maudelondé, Thierry Fest, Catherine Alix‐Panabières · 2015 · Molecular Oncology
59. Cancer prevention and therapy through the modulation of the tumor microenvironment
    Stephanie C. Casey, Amedeo Amedei, Katia Aquilano, Asfar Sohail Azmi, Fabián Benencia, Dipita Bhakta-Guha, Alan E Bilsland, Chandra Shekhar Boosani, Sophie Chen, Maria Rosa Ciriolo et al. · 2015 · Seminars in Cancer Biology
60. A panoply of errors: polymerase proofreading domain mutations in cancer
    Emily Rayner, Inge C. van Gool, Claire Palles, Stephen E. Kearsey, Tjalling Bosse, Ian P.M. Tomlinson, David N. Church · 2016 · Nature reviews. Cancer
61. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma
    Orillion, Ashley, Hashimoto, Ayumi, Damayanti, Nur, Shen, Li, Adelaiye-Ogala, Remi, Arisa, Sreevani, Chintala, Sreenivasulu, Ordentlich, Peter, Kao, Chingai, Elzey, Bennett et al. · 2017 · Clinical Cancer Research
62. At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
    Andrew M. Intlekofer, Craig B. Thompson · 2013 · Journal of Leukocyte Biology
63. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion
    John David Klement, Amy V. Paschall, Priscilla S. Redd, Mohammed L. Ibrahim, Chunwan Lu, Dafeng Yang, Esteban Celis, Scott I. Abrams, Keiko Ozato, Kebin Liu · 2018 · Journal of Clinical Investigation
64. The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives
    Wang, Shun, Zheng, Yan, Yang, Feng, Zhu, Le, Zhu, Xiao-Qiang, Wang, Zhe-Fang, Wu, Xiao-Lin, Zhou, Cheng-Hui, Yan, Jia-Yan, Hu, Bei-Yuan et al. · 2021 · Signal Transduction and Targeted Therapy
65. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
    Yuan Liu, Yufeng Cheng, Yong Xu, Zhifeng Wang, Xianhong Du, Chunyang Li, Jiali Peng, Lifen Gao, Xiaohong Liang, Chunhong Ma · 2017 · Oncogene
66. Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States
    Anna E. Coghill, Meredith S. Shiels, Gita Suneja, Eric A. Engels · 2015 · Journal of Clinical Oncology
67. Epigenetic Therapeutics: A New Weapon in the War Against Cancer
    Nita Ahuja, Anup R. Sharma, Stephen B. Baylin · 2016 · Annual Review of Medicine
68. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance
    Xiaowei Liu, Jinen Song, Hao Zhang, Xinyu Liu, Fengli Zuo, Yunuo Zhao, Yujie Zhao, Xiaomeng Yin, Xinyu Guo, Xi Lawrence Wu et al. · 2023 · Cancer Cell
69. Implications of the tumor immune microenvironment for staging and therapeutics
    Janis Marie Taube, Jérôme Galon, Lynette Marie Sholl, Scott J. Rodig, Tricia R. Cottrell, Nicolás A. Giraldo, Alexander Spyridon Baras, Sanjay S. Patel, Robert A. Anders, David L. Rimm et al. · 2017 · Modern Pathology
70. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
    Long, Long, Zhang, Xue, Chen, Fuchun, Pan, Qi, Phiphatwatchara, Pronnaphat, Zeng, Yuyang, Chen, Honglei · 2018 · Genes &amp; Cancer
71. The role of CD95 and CD95 ligand in cancer
    Marcus E. Peter, A Hadji, Andrea E. Murmann, Sonia Brockway, William Putzbach, Abhinandan Pattanayak, Paolo Ceppi · 2015 · Cell Death and Differentiation
72. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
    Maddalena Centanni, Dirk Jan A. R. Moes, Iñaki F. Trocóniz, Joseph Ciccolini, J. G. Coen van Hasselt · 2019 · Clinical Pharmacokinetics
73. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response
    Feifei Hu, Chunjie Liu, Lanlan Liu, Qiong Zhang, An‐Yuan Guo · 2020 · Briefings in Bioinformatics
74. Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
    Albrecht Neeße, Christian Alexander Bauer, Daniel Öhlund, Matthias Lauth, Malte Buchholz, Patrick Michl, David A. Tuveson, Thomas Mathias Gress · 2018 · Gut
75. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
    Flint, Thomas R., Janowitz, Tobias, Connell, Claire M., Roberts, Edward W., Denton, Alice E., Coll, Anthony P., Jodrell, Duncan I., Fearon, Douglas T. · 2016 · Cell Metabolism
76. MHC-I Genotype Restricts the Oncogenic Mutational Landscape
    Rachel Marty, Saghar Kaabinejadian, David Rossell, Michael J. Slifker, Joris van de Haar, Hatice Billur Engin, Nicola de Prisco, Trey E. Ideker, William H. Hildebrand, Joan Font-Burgada et al. · 2017 · Cell
77. PD-L1 and Survival in Solid Tumors: A Meta-Analysis
    Pin Wu, Dang Wu, Li‐Jun Li, Ying Chai, Jian Huang · 2015 · PLoS ONE
78. Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
    Philipp Müller, Matthias Kreuzaler, Tarik A. Khan, Daniela S. Thommen, Kea Martin, Katharina Glatz, Spasenija Savic, Nadia Harbeck, Ulrike Anneliese Nitz, Oleg Gluz et al. · 2015 · Science Translational Medicine
79. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
    Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ikuo Konishi · 2016 · International Journal of Clinical Oncology
80. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy
    Chao Liu, Xue Liu, Xinchu Xiang, Xin Pang, Siyuan Chen, Yunming Zhang, En Ren, Lili Zhang, Xuan Liu, Peng Lv et al. · 2022 · Nature Nanotechnology
81. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
    Zuqiang Liu, Roshni Ravindranathan, Paweł Kaliński, Zong Sheng Guo, David L. Bartlett · 2017 · Nature Communications
82. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    Jianchun Duan, Longgang Cui, Xiaochen Zhao, Hua Bai, Shangli Cai, Guoqiang Wang, Zhengyi Zhao, Jing Zhao, Shiqing Chen, Jia Song et al. · 2019 · JAMA Oncology
83. Cancer Epigenetics, Tumor Immunity, and Immunotherapy
    Jian Cao, Qin Yan · 2020 · Trends in Cancer
84. At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
    Margaret K. Callahan, Jedd D. Wolchok · 2013 · Journal of Leukocyte Biology
85. Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
    Jing W. Hughes, Nalini Kumar Vudattu, Mario Sznol, Scott N. Gettinger, Harriet M. Kluger, Beatrice C. Lupsa, Kevan C. Herold · 2015 · Diabetes Care
86. Versatile roles of extracellular vesicles in cancer
    Nobuyoshi Kosaka, Yusuke Yoshioka, Yu Fujita, Takahiro Ochiya · 2016 · Journal of Clinical Investigation
87. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
    Mélodie Tazdait, Laura Mezquita, Jihene Lahmar, Roberto Ferrara, François Bidault, Samy Ammari, Corinne Balleyguier, David Planchard, Anas Gazzah, Jean‐Charles Soria et al. · 2017 · European Journal of Cancer
88. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    Daniel Sanghoon Shin, Antoni Ribas · 2015 · Current Opinion in Immunology
89. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
    Liisa Chang, Minna Chang, Hanna M. Chang, Fuju Chang · 2017 · Applied immunohistochemistry & molecular morphology
90. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells
    Teresa Manzo, Boone M. Prentice, Kristin G. Anderson, Ayush T. Raman, Aislyn P. Schalck, Gabriela S. Codreanu, Carina B. Nava Lauson, Silvia Tiberti, Andrea Raimondi, Marissa A. Jones et al. · 2020 · The Journal of Experimental Medicine
91. Immune Cell Composition in Human Non-small Cell Lung Cancer
    Branislava Stankovic, Heidi Anine Korsmo Bjørhovde, Renate Skarshaug, Henrik Aamodt, Astri Frafjord, Elisabeth Müller, Clara Louise Hammarström, Kahsai Beraki, Espen S. Bækkevold, Per Reidar Woldbæk et al. · 2019 · Frontiers in Immunology
92. Treatment of Advanced Melanoma in 2020 and Beyond
    Russell William Jenkins, David E. Fisher · 2020 · Journal of Investigative Dermatology
93. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
    Hong Zheng, Weipeng Zhao, Cihui Yan, Crystina C. Watson, Michael T. Massengill, Mengyu Xie, Chris Massengill, David R. Noyes, Gary V. Martinez, Roha Afzal et al. · 2016 · Clinical Cancer Research
94. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
    Charlotte M. Roach, Nancy Zhang, Ellie Corigliano, Malinka Jansson, Grant Toland, Gary Ponto, Marisa P Dolled-Filhart, Kenneth Emancipator, Dave Stanforth, Karina Kulangara · 2016 · Applied immunohistochemistry & molecular morphology
95. Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy
    Constantinidou, Anastasia, Alifieris, Constantinos, Trafalis, Dimitrios T. · 2019 · Pharmacology &amp; Therapeutics
96. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
    Eloah Rabello Suarez, De-Kuan Chang, Jiusong Sun, Jianhua Sui, Gordon James Freeman, Sabina Signoretti, Quan Karen Zhu, Wayne Anthony Marasco · 2016 · Oncotarget
97. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape
    Garg, Abhishek D., Coulie, Pierre G., Van den Eynde, Benoit J., Agostinis, Patrizia · 2017 · Trends in Immunology
98. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
    Yaqing Zhang, Ashley Velez-Delgado, Esha Mathew, Dongjun Li, Flor Mendez, Kevin Flannagan, Andrew D. Rhim, Diane M. Simeone, Gregory Lawrence Beatty, Marina Pasca di Magliano · 2016 · Gut
99. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
    Blando, Jorge, Sharma, Anu, Higa, Maria Gisela, Zhao, Hao, Vence, Luis, Yadav, Shalini S., Kim, Jiseong, Sepulveda, Alejandro M., Sharp, Michael, Maitra, Anirban et al. · 2019 · Proceedings of the National Academy of Sciences
100. From mice to humans: developments in cancer immunoediting
     Teng, Michele W.L., Galon, Jerome, Fridman, Wolf-Herman, Smyth, Mark J. · 2015 · Journal of Clinical Investigation